Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$100,000.00
Aug 1, 2018
Combining oncolytic virotherapy and epigenetic modifiers to treat acute leukemias
$67,000.00
Aug 1, 2018
The proteogenomic landscape of tumour-specific antigens present in triplenegative breast cancers
$100,000.00
Aug 1, 2018
Reprogramming tumour immunogenicity with STING-Nanoparticles
$90,000.00
Aug 1, 2018
The Role of Scaffold Proteins in Cytokinesis and Ciliogenesis in Human Cells
$62,000.00
Aug 1, 2018
Reconceptualizing cancer metastasis as a balance of intra-tumoural mechanical forces
$65,000.00
Aug 1, 2018
Targeting aryl hydrocarbon receptor as novel vulnerability in triple negative breast cancers
$99,610.00
Aug 1, 2018
BRCA2-deficient fibroblasts in tumour promotion
$140,000.00
Aug 1, 2018
Circulating blood: Medical supply chains and infrastructure disruption
$66,000.00
Aug 1, 2018
Immune-stimulatory antibody-drug conjugates for treatment of breast cancer
$140,000.00
Aug 1, 2018
Developing an entirely new anti-vascular therapy approach to treat metastatic cancer by targeting vessel co-option